Jane Street Group LLC Purchases New Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Jane Street Group LLC bought a new stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,907 shares of the company’s stock, valued at approximately $56,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers bought a new stake in shares of Eliem Therapeutics in the 2nd quarter valued at about $59,000. SG Americas Securities LLC purchased a new position in Eliem Therapeutics during the third quarter worth about $60,000. Valence8 US LP purchased a new stake in shares of Eliem Therapeutics in the 3rd quarter valued at approximately $61,000. Chicago Partners Investment Group LLC acquired a new stake in Eliem Therapeutics during the 3rd quarter worth approximately $81,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Eliem Therapeutics in the 2nd quarter valued at $89,000. Institutional investors own 69.76% of the company’s stock.

Eliem Therapeutics Price Performance

Shares of ELYM opened at $1.87 on Thursday. The firm has a fifty day moving average price of $2.72 and a 200 day moving average price of $5.12. Eliem Therapeutics, Inc. has a 1-year low of $2.35 and a 1-year high of $11.55. The stock has a market cap of $55.64 million, a PE ratio of -3.53 and a beta of -0.39.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.